Biogen is advancing its experimental Alzheimer’s drug, Diranersen, to late-stage Phase 3 testing despite mixed results from mid-stage trials, where higher doses failed to show improved responses. The decision stems from indications that the drug may reduce tau protein levels and slow cognitive decline, particularly at lower doses. Dr. Priya Singhal, Biogen’s head of development, emphasized the significance of these findings, highlighting the combination of tau reduction and cognitive benefits as key criteria for moving forward.
This development is critical for the financial markets as it underscores Biogen’s ongoing commitment to Alzheimer’s research, a sector that has seen volatility due to mixed trial results and regulatory scrutiny. The company’s previous drugs, Aduhelm and Leqembi, have faced challenges, which could impact investor sentiment and stock performance.
For market professionals, the key takeaway is that Biogen’s decision to proceed with Phase 3 testing may influence its stock trajectory and signal renewed interest in Alzheimer’s treatments, particularly as competition from rivals like Eli Lilly intensifies.
Source: cnbc.com